Muftuoglu, M., Hong, E., Farhadfar, N., Strickland, S., Bajel, A., Eghtedar, A., Schiller, G., Basyal, M., Li, L., Naitmazi, L., Emery, R., Lu, T., Garrison, B., Rajangam, K., Ravandi, F., Andreeff, M. (2025). Correlative data from an ongoing Phase 1, multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML) is consistent with its clinical activity and unique logic gated mechanism of action. Blood. https://doi.org/10.1182/blood-2025-5921